Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2404991 | Vaccine | 2009 | 10 Pages |
Abstract
Development of a protective subunit vaccine against Leishmania spp. depends on antigens and adjuvants that induce appropriate immune responses. We evaluated a second generation polyprotein antigen (Leish-110f) in different adjuvant formulations for immunogenicity and protective efficacy against Leishmania spp. challenges. Vaccine-induced protection was associated with antibody and T cell responses to Leish-110f. CD4 T cells were the source of IFN-γ, TNF, and IL-2 double- and triple-positive populations. This study establishes the immunogenicity and protective efficacy of the improved Leish-110f subunit vaccine antigen adjuvanted with natural (MPL-SE) or synthetic (EM005) Toll-like receptor 4 agonists.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Sylvie Bertholet, Yasuyuki Goto, Lauren Carter, Ajay Bhatia, Randall F. Howard, Darrick Carter, Rhea N. Coler, Thomas S. Vedvick, Steven G. Reed,